Novel Bruton’s Tyrosine Kinase inhibitor remibrutinib: Drug‐drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling

by Felix Huth, Hilmar Schiller, Yi Jin, Birk Poller, Carole Schuhler, Wendy Weis, Ralph Woessner, Anton Drollmann, Peter End
Published 2022-01-01

Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial

by Martin Kaul, Peter End, Maciej Cabanski, Carole Schuhler, Annamaria Jakab, Magdalena Kistowska, Arvind Kinhikar, Alessio Maiolica, Angela Sinn, Rainard Fuhr, Bruno Cenni
Published 2021-09-01